2022
The current state of the art and future trends in RAS-targeted cancer therapies
Punekar S, Velcheti V, Neel B, Wong K. The current state of the art and future trends in RAS-targeted cancer therapies. Nature Reviews Clinical Oncology 2022, 19: 637-655. PMID: 36028717, PMCID: PMC9412785, DOI: 10.1038/s41571-022-00671-9.Peer-Reviewed Original ResearchConceptsDuration of responseNovel combination therapiesCombination therapyClinical trialsTherapeutic strategiesSolid tumorsMutant KRASTumor microenvironmentDrug resistanceRAS pathwayCancer cellsDevelopment of inhibitorsCancer therapyOncogenic RASPatientsOncogenic proteinsTherapyKRASResistance mechanismsMutant isoformsInhibitorsRASMalignancyTumorsCancer
2019
Novel Therapeutics Affecting Metabolic Pathways
Punekar S, Cho D. Novel Therapeutics Affecting Metabolic Pathways. American Society Of Clinical Oncology Educational Book 2019, 39: e79-e87. PMID: 31099667, DOI: 10.1200/edbk_238499.Peer-Reviewed Original ResearchConceptsIntratumoral metabolic heterogeneityMetabolic heterogeneityImmune factorsNovel agentsTherapeutic strategiesTumor microenvironmentNovel therapeuticsDistinct metabolic characteristicsCancer cellsMetabolic characteristicsCombination strategiesNormal cellsCell growthSpecific metabolic processesCitric acid cycle